- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01058824
Relative Bioavailability Study Of Two Lincomycin Hydrochloride Hard Gelatinous Capsule
April 25, 2011 updated by: Pfizer
Relative Bioavailability Study Of Two Lincomycin Hydrochloride Hard Gelatinous Capsule 500 Mg Formulations, In Healthy Volunteers Using Formulations (Frademicina®) Manufactured By Pfizer Laboratories Ltd
To assess the relative bioavailability of two different batches of Frademicina® drug product, containing 500 mg lincomycin hydrocloride, manufactured by Pfizer Laboratories Ltd.
The formulations' comparative bioavailability after oral administration will be assessed based on the statistical comparisons of the relevant pharmacokinetic parameters, obtained from the drug concentrations in the blood.
The lincomycin hydrocloride concentration will be measured by a proper and validated analytical method.
Study Overview
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Sao Paulo
-
Campinas, Sao Paulo, Brazil, 13012-000
- Pfizer Investigational Site
-
Campinas, Sao Paulo, Brazil, 13012-431
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 48 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men.
- Women who are not pregnant nor nursing.
- Age between 18 and 50 years-old.
- Body mass index ≥ 19 and ≤ 28,5.
- Good health conditions or with no significant diseases, under judgement of the legally qualified professional, according to the rules defined in the Protocol, and based on the following assessments: clinical history, pressure and pulse measurements, physical and psychological examination, ECG and complementary laboratorial tests.
- Ability to understand the nature and the objective of the trial, including the risks and adverse effects and, agreeing to cooperate with the investigator and to act according to the requirements of the whole assay, which will be confirmed through the signature of the Free Informed Consent.
Exclusion Criteria:
- Known hypersensitivity to the study drug (lincomycin hydrocloride) or to compounds chemically related.
- History or presence of hepatic, gastrointestinal diseases or other conditions that may interfere with the absorption, distribution, excretion or metabolism process of the drug.
- History of hepatic, renal, pulmonary, gastrointestinal, epileptic, hematological or psychiatric condition; of hypo or hypertension from any etiology that require pharmacological treatment; history or had myocardial infarction, angina and/or cardiac insufficiency.
- Electrocardiographic findings non-recommended for the enrollment in the trial, by investigator's criteria.
- Results of the laboratory tests are out of the normal range, according to the standards of this protocol, unless they are considered clinically irrelevant by the investigator.
- He/She is a smoker.
- Drinks more than 05 cups of coffee or tea per day.
- History of alcohol or drug abuse.
- Use of regular medication within 02 weeks prior to the beginning of the treatment and to the assessment date; or use of any medication within a week, except for contraceptive medications.
- Hospitalization for any reason within 08 weeks prior to the beginning of the first treatment period of this trial and to the assessment date.
- Treatment within 03 months prior to the trial with any drug with known toxic potential on primary organs.
- Enrollment to any experimental trial or use of any experimental drug within 06 months prior to the beginning of this trial and to the assessment date.
- Donation or loss of 450 mL or more of blood within 03 months that precede the trial or donation higher than 1500 mL within the 12 months between the beginning of the clinical trial and the assessment date.
- Consumption of inducing and/or inhibiting enzymatic drugs (CYP450 - hepatic), toxic to organ or with long half-life period, within 04 weeks prior to the beginning of the trial.
- Consumption of alcohol within 48 hours preceding the enrollment to the trial and during the clinical trial.
- Consumption of food and beverages that contained grapefruit up to 07 days prior to each trial period.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Lincomycin - Active Comparative - Hard Gelatin Capsule
|
Single Dose Hard Gelatin Capsule - oral - 500 mg
Other Names:
|
Experimental: Lincomycin - Study Drug - Hard Gelatin Capsule
|
Single Dose Hard Gelatin Capsule - oral - 500 mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUC [0-t]Area under the curve of concentration vs. time, from time 0 (zero) up to the time of the last observed concentration above the limit of quantification, calculated by the trapezium rules.
Time Frame: 1 week
|
1 week
|
Cmax Maximum reached concentration, based on the experimental data, obtained directly from the curve concentration vs. time;
Time Frame: 1 week
|
1 week
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUC [0-¥]Area under the curve of drug concentration versus time, from time 0 (zero) extrapolated to the infinite, calculated as AUC [0-¥] = AUC [0-t] + Ct/Ke, in which Ct is the last concentration determined above the limit of
Time Frame: 1 week
|
1 week
|
quantification.
Time Frame: 1 week
|
1 week
|
Ke Terminal First Order Elimination Constant, estimated by the angular coefficient of the linear regression, calculated by the Least Square Method, from the natural logarithms of concentration vs. time to the last four values of concentration (or at
Time Frame: 1 week
|
1 week
|
least three) above the limit of quantification.
Time Frame: 1 week
|
1 week
|
T½ Half-life time, calculated as ln (2) / Ke.
Time Frame: 1 week
|
1 week
|
Adverse events and vital signs.
Time Frame: 1 week
|
1 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2009
Primary Completion (Actual)
April 1, 2009
Study Completion (Actual)
April 1, 2009
Study Registration Dates
First Submitted
January 27, 2010
First Submitted That Met QC Criteria
January 27, 2010
First Posted (Estimate)
January 29, 2010
Study Record Updates
Last Update Posted (Estimate)
April 26, 2011
Last Update Submitted That Met QC Criteria
April 25, 2011
Last Verified
April 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- B1601001
- STPh40/09
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bacterial Infections
-
Sir Run Run Shaw HospitalUniversity of BirminghamUnknown
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
GlaxoSmithKlineWithdrawn
-
GlaxoSmithKlineWithdrawn
Clinical Trials on Lincomycin
-
University of MelbourneRadboud University Medical Center; Sunnybrook Health Sciences Centre; UMC Utrecht and other collaboratorsRecruitingStaphylococcus Aureus BacteremiaAustralia, New Zealand, Canada, Singapore, Netherlands, Israel
-
National and Kapodistrian University of AthensUniversity of Oxford; Naval Hospital of Athens; Biomedical Research Foundation...RecruitingAortic Valve Stenosis | Calcific Aortic Valve Disease | Aortic Valve, Calcification ofGreece
-
Julio RamirezUniversity of LouisvilleTerminatedOsteomyelitisUnited States